Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.41 |
| ▸ | POLG | P54098 | 2/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.36 |
| ▸ | ENTPD1 | P49961 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23047623 | 0.91 | POLRMT (0.50) | POLRMTP2RX1P2RX3P2RX4P2RX2 | |
| SCHEMBL4765352 | 0.84 | POLRMT (0.53) | POLRMTP2RX1P2RX3P2RX4P2RX2 | |
| SCHEMBL10143054 | 0.83 | POLRMT (0.49) | POLRMTP2RX1P2RX3P2RX4P2RX2 | |
| SCHEMBL10120887 | 0.83 | POLRMT (0.53) | POLRMTP2RX1P2RX3P2RX4P2RX2 | |
| SCHEMBL15998230 | 0.81 | POLRMT (0.50) | POLRMTP2RX1P2RX3P2RX4P2RX2 | |
| SCHEMBL24074599 | 0.81 | POLRMT (0.49) | POLRMTP2RX1P2RX3P2RX4P2RX2 | |
| SCHEMBL10154383 | 0.81 | RIPK1 (0.31) | POLRMT | |
| SCHEMBL882157 | 0.80 | POLRMT (0.45) | POLRMTP2RX1P2RX3P2RX4P2RX2 | |
| SCHEMBL23047655 | 0.80 | POLRMT (0.49) | POLRMTP2RX1P2RX3P2RX4P2RX2 | |
| SCHEMBL19504899 | 0.78 | POLRMT (0.47) | POLRMTP2RX1P2RX3P2RX4POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021154687-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-20120107274-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107274-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NUDT1, SLC29A2 | POLRMT 103/4885P2RX1 133/4885P2RX3 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.